The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Ratain, Mark J.
One or more keywords matched the following items that are connected to Ratain, Mark J.
Item TypeName
Concept Research Design
Academic Article Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
Academic Article Learning from our patients: one participant's impact on clinical trial research and informed consent.
Academic Article Development of target-based antineoplastic agents.
Academic Article Clinical trial designs for cytostatic agents.
Academic Article Randomized discontinuation design: application to cytostatic antineoplastic agents.
Academic Article Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
Academic Article Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
Academic Article Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
Academic Article Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Academic Article Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
Academic Article The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
Academic Article The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Academic Article Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
Academic Article Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
Academic Article Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.
Academic Article The investigational drug steering committee.
Academic Article Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
Academic Article Optimising the design of phase II oncology trials: the importance of randomisation.
Academic Article Resampling phase III data to assess phase II trial designs and endpoints.
Academic Article Randomized phase II trials: a long-term investment with promising returns.
Academic Article Dose-escalation models for combination phase I trials in oncology.
Academic Article Perceptions of cancer patients and their physicians involved in phase I trials.
Academic Article Measuring response in a post-RECIST world: from black and white to shades of grey.
Academic Article Opportunities and challenges in the development of experimental drug combinations for cancer.
Academic Article Cancer pharmacogenomics: strategies and challenges.
Academic Article Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
Academic Article Targeted therapies: redefining the primary objective of phase I oncology trials.
Academic Article Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
Academic Article Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials.
Academic Article Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Search Criteria
  • Research Design